CELL INTELLIGENCE · 肿瘤细胞治疗研究

CD19/CD22 双价 CAR-T 细胞治疗儿童、青少年与年轻成人 B-ALL：1 期试验最终结果

CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results.

人源 CAR-T22.19 治疗难治性儿童 B-ALL：指定患者队列的启示

Human CART22.19 therapy in refractory pediatric B-ALL: insights from a named-patient cohort.

CAR-T22.19 疗法在高危儿科人群中显示出良好的安全性特征和有前景的临床活性，其双靶向设计使 CD19 阴性白血病获得疾病控制。

异基因 HSCT 复发后供者来源干细胞记忆 CAR-T 细胞的独特体内动力学

Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse.

CAR-T 细胞治疗在儿童急性淋巴细胞白血病中的应用：面向普通儿科医师的综述

CART-Cell Therapy in Pediatric Acute Lymphoblastic Leukemia: A Review for General Pediatricians.

复发/难治性大 B 细胞淋巴瘤患者中 CD19 靶向治疗的序贯策略：一篇叙述性综述

Sequencing CD19-targeted therapies in patients with relapsed/refractory large B-cell lymphoma: A narrative review.

大 B 细胞淋巴瘤中 CD19 CAR-T 治疗前的 B 细胞靶向免疫治疗暴露与 CD19 CAR-T 后结局：一项 EBMT 注册研究分析

Pre-CAR-T B-cell-directed immunotherapy exposure and outcomes after CD19 CAR-T for large B-cell lymphoma: An EBMT registry analysis.

供者来源 CD19 靶向 CAR-NK 细胞在 blinatumomab 和自体 CD19 靶向 CAR-T 治疗失败后诱导复发 B-ALL 患儿完全缓解

Donor-derived CD19-targeted CAR-NK cells induce complete remission in a child with relapsed B-ALL after failure of blinatumomab and autologous CD19-ta

接受 CD19 CAR-T 细胞治疗的复发/难治性弥漫大 B 细胞淋巴瘤患者中脑至静脉时间的种族与民族差异

Racial and ethnic disparities in brain-to-vein time among patients receiving CD19 CAR-T cell therapy for relapsed/refractory DLBCL.

Cre 依赖性基因表达使靶向肿瘤相关抗原的自身反应性 CAR-T 细胞实现胸腺发育

Cre-dependent gene expression enables thymic development of autoreactive tumor-associated antigen targeting CAR-T cells.

obecabtagene autoleucel 与外部对照臂在复发/难治性 B 细胞急性淋巴细胞白血病成人患者中的比较

Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.